Today: December 11, 2018, 1:08 am
  
Business

Oxford Immunotec Announces Regulatory Acceptance of T-Cell Select™ in China

PR-Inside.com: 2018-12-07 15:01:02

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Select kit by the China Food and Drug Administration (CFDA).

The T-Cell Select kit was designed as an immune cell separation reagent kit to simplify workflow, improve throughput, and reduce hands-on time and labor costs in performing the T-SPOT®.TB test. With the T-Cell Select kit, blood samples collected in a single standard blood tube can be stored for up to 54 hours at room temperature before use, further extending the company’s unrivaled simplicity and logistics advantages for customers.

For additional information, please visit: http://www.oxfordimmunotec.com/international/products-services/t-cell-select/.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company's T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT, T-Cell Select and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

Forward-Looking Statements

This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this release are forward-looking statements. This includes statements about Oxford Immunotec's anticipated plans and objectives, future performance and revenues, financial condition, prospects for sales of its products, growth, strategies, expectations and objectives of management. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements contained in this release reflect Oxford Immunotec's current expectations and are subject to risks and uncertainties. Actual results may differ materially from those projected or implied by forward-looking statements. Other factors that could adversely affect Oxford Immunotec's business and prospects are described under the "Risk Factors" section in its filings with the Securities and Exchange Commission ("SEC"). Oxford Immunotec's SEC filings are available for free by visiting the investor section of its website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACTS:

For Media and Investor Inquiries:
Karen Koski
VP, Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com




# 745 Words
Related Articles
More From The Author
Akastor ASA: First Geo and AGR combine [..]
Akastor ASA (OSE: AKA), through its wholly owned subsidiary Akastor AS (Akastor), has today entered into agreements with Silverfleet [..]
Orchard Therapeutics Appoints Industry Veteran Alicia Secor [..]
BOSTON and LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical [..]
Vestas reinforces its leadership in Italy with [..]
News release from Vestas Mediterranean Madrid, 7 December 2018 Adding to the more than 1 GW of contracts signed by Vestas [..]
OLVI PLC TO INITIATE REPURCHASE OF SHARES
OLVI OYJ                STOCK EXCHANGE RELEASE 7 Dec 2018 at 2.00 pm OLVI PLC TO INITIATE REPURCHASE OF SHARES In [..]
Medtronic Announces Cash Dividend for Third Quarter [..]
DUBLIN - December 7, 2018 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2019 [..]
 
More From Business
GTA Boosting Offers the Best Way to [..]
10 December 2018 – GTA Boosting is offering the most effective and straightforward way to buy gta online money in [..]
Purtier Sales Is The Amazing New Solution [..]
Los Angeles, USA — 6 December 2018 — Purtier Sales is the web site that encourages people to buy the [..]
GPU Servers Offers the Best Quality Service
6 December 2018 – GPU Servers is offering the very best way to make the most from the gpu dedicated [..]
Limo and Party Bus Rentals in Toronto
Toronto, Canada – 06 December 2018 – Toronto Limo Rentals offers top quality limo rental services, while delivering their [..]
The Best Online Magazine of India
New Delhi, India –5 December 2018 – News4Social offers the hottest news from India and the entire world along with [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.